Shares in diabetes drug company Biodel have fallen considerably following questionable results in a late-stage human drug trial for a new type of diabetes medication.
The pharmaceutical company submitted two sets of results for diabetes drug VIAject at a conference in Romen, and one was found to have questionable results. VIAject was compared with Humulin (Eli Lilly) to assess whether the drug stabilised blood sugar and reduced weight gain amongst people with type 2 diabetes .
The team conducted the trials in India, the United Stated and Germany – but excluded the data from the type 1 diabetes study in India. The company are understood to be investigating the anomalies and submitting the data to the FDA. How the situation resolves remains to be seen.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…